---
document_datetime: 2024-07-18 11:42:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ixchiq-epar-all-authorised-presentations_en.pdf
document_name: ixchiq-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3518579
conversion_datetime: 2025-12-29 23:11:26.485187
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

EU/1/24/1828/001 IXCHIQ --¹ Powder and solvent for solution for injection Intramuscular use powder: vial (glass); solvent: pre-filled syringe (glass) 0.5 ml 1 vial + 1 pre-filled syringe

--¹ After reconstitution, one dose (0.5 mL) contains: Chikungunya virus (CHIKV) Δ5nsP3 strain (live, attenuated)* not less than 3.0 log10 TCID50**

* Produced in Vero cells ** 50% tissue culture infectious dose